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Obesity is the most common asthma co-morbidity; it has been associated with increased risk for asthma exacerbations,
worse respiratory symptoms and poor control. The exact mechanisms remain elusive and are probably multifactorial,
stemming from mechanical alterations of the airways and lung parenchyma, to systemic and airway inflammatory and
metabolic dysregulation that adversely influences lung function and or response to therapy. However, the fact that
not every obese asthmatic is equally affected by weight gain highlights the many challenges and complexities in
understanding this association. The factors that determine susceptibility may not depend on being obese alone,
but rather the interactions with other phenotypical characteristics, such as age of asthma onset, gender and race
to name a few. Inability to account for asthma phenotypes that are differentially affected by increasing body
mass index (BMI) may contribute to the lack of consistent results across studies. This review will provide a succinct
summary of obesity-related mechanisms and the clinical impact on asthma including highlights on recent progress.
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Approximately 38 % of current adult asthmatics are also
obese in the United States, and obesity has been shown
to be risk factor for developing asthma. Obese asth-
matics reports worse asthma control despite traditional
asthma therapy, worse asthma-specific quality of life,
and higher rates of healthcare utilization; however, the
mechanisms driving this association remain unclear. Un-
derstanding the link between obesity and asthma may
have major public health implications and has the poten-
tial to lead to development of future therapies. This re-
view will give a concise examination of the association
between asthma and obesity and provide conclusions on
the current body of literature.Review
The epidemiology of the obesity and asthma association
Obesity is associated with greater asthma morbidity and
with increased prevalence and incidence rates. These
associations have been inconsistently reported in males
and females, across different races, and among all age
groups. The heterogeneity of study results highlights the* Correspondence: holguinf@upmc.edu
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association, including such issues as diagnostic bias, bi-
directionality, differing asthma case definitions, and study
designs. Despite these limitations, there is a general con-
sensus from the existing literature that weight gain and
obesity adversely affects the respiratory health of millions
of subjects with and without asthma.
In a recent meta-analysis of 7 longitudinal cohort stud-
ies involving over 300,000 adults, there was a dose re-
sponse effect between increasing BMI and the odds ratio
(OR) of incident asthma. Compared to normal weight, a
BMI ≥ 25 was associated with an OR of 1.5 (95 % CI; 1.2 –
1.6), whereas the OR for a BMI > 30 was 1.9 (95 % CI;
1.4 – 2.6), while similar ORs were observed in males
and females [1]. Although these results strongly suggest
a potential causal relationship, they were based on self-
reported asthma and therefore more susceptible to diag-
nostic biases. In fact, when using stricter diagnostic criteria
such as bronchial hyperresponsiveness, the obese – asthma
association is less consistent, and obese subjects may be er-
roneously diagnosed as having asthma [2, 3]. Therefore,
the extent by which greater BMI increases the likelihood of
being diagnosed with asthma, independently of bias, re-
mains unknown. A different question, however, is the role
of obesity as a co-morbidity. As it has been shown inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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index (BMI) strongly influences asthma control and se-
verity [3]. Even when fully compliant and in accordance
with treatment guidelines, having a BMI above normal
diminished the probability of achieving adequate symp-
tom control. Obesity is also linked to more frequent and
severe respiratory symptoms. In the Centers for Disease
Control (CDC) four state (Alabama, California, Texas, and
Illinois) sample of the National Asthma Survey, those with
a BMI > 30 had more daily symptoms, used rescue in-
halers more frequently, and were less likely to achieve re-
mission [4]. Given that on average obese asthmatics, both
children and adults, are more symptomatic and poorly
controlled, it is not surprising that studies have shown
them to have increased rates of healthcare utilization and
greater healthcare expenditure [5, 6], though this has not
been uniformly shown across studies [7].
Are obese asthmatics a unique clinical phenotype?
An important unanswered question is whether being
obese and having asthma constitutes a unique clinical
phenotype; in other words, does the interaction of obes-
ity (as an environmental risk factor) with underlying
genetic traits (or other host susceptibility factors) lead to
a set of defined observable traits? If this were correct, all
asthmatics with a BMI > 30 would share unique clinical
characteristics; however, given that patients with differ-
ent clinical asthma phenotypes can be obese, and not
every asthmatic seems to be equally impacted by weight
gain, this idea seems rather simplistic. To further illus-
trate this point, in the Severe Asthma Research Program
(SARP) cluster study, the proportion of obesity across
the 5 asthma phenotype clusters ranged from 24 – 51 %,
and it was greater than a third of the population in all of
the clusters except for cluster 1 [8]. However, clinical
characteristics associated with the highest BMI cluster
that have been consistently described across studies in-
clude having late onset asthma, lower exhaled nitric oxide
(eNO) levels, less airway eosinophils, and reduced atopy
[8–10]. Asthmatics in this cluster are disproportionally
symptomatic for the level of airway inflammation or
functional impairment and have a high rate of controller
medication usage and healthcare utilization. Unfortu-
nately, given the cross sectional comparison between
cluster groups, it is unknown whether obesity antecedes
the development of these phenotypical characteristics
or whether subjects in this cluster are more likely to
gain weight. This leads to another unanswered question;
is obesity a risk factor for or a consequence of increased
asthma severity? The response may depend on how it
relates to additional phenotypical factors. For example,
in a cross sectional study of the SARP study population,
the relationship between BMI and duration of asthma
(in years) varied with regard to whether the onset ofasthma was early or late (before or after 12 years of age)
[5]. In the early onset category, independent of other
confounders, BMI increased linearly for every year of
having asthma since diagnosis; in contrast, there was no
association in the late onset group. One possible inter-
pretation is that in contrast to the later onset asthma,
early onset is a potential risk factor for weight gain.
However, it remains to be determined whether obesity
that antecedes or occurs after an asthma diagnosis im-
pacts asthma severity or control any differently.
Impact of obesity on asthma control
Different anthropometric measures, including BMI or
other adiposity indexes, have been shown to be significant
determinants of asthma control for adults in some studies,
even when adjusting for other confounders [11–13]. In
contrast, other studies have failed to show this trend. For
example, in a predominantly African American adult,
inner city asthma population, increasing BMI was not
shown to be independently associated with decrements in
the asthma control questionnaire (ACQ) or asthma con-
trol test (ACT) [7]. Although on average this study popu-
lation was poorly controlled and had a high healthcare
utilization rate, there were no associated trends with in-
creasing BMI. In a large study of 2,174 children participat-
ing in the Genes-environments and Admixture in Latino
Americans (GALA II) Study and the Study of African
Americans, Asthma, Genes, and Environments (SAGE II),
obesity increased the odds of being poorly controlled
(defined by the American Thoracic Society guidelines)
by 33 % in boys. Interestingly, this association was
modified by ethnicity and race in girls, in whom obesity
increased the OR for poor control in Latinos, but not in
African Americans [14].
Overall, increasing BMI can adversely influence asthma
control; however, the direction and magnitude of this as-
sociation will depend on how the study population is con-
stituted, specifically, the proportions of different asthma
phenotypes (i.e. race, age of onset, and gender), some of
which may be more or less affected by having greater adi-
posity or BMI.
Potential mechanisms
There are multiple mechanisms by which obesity can
potentially worsen asthma, including its effects on pul-
monary physiology and mechanics. Increasing weight
gain can have profound implications on lung physiology,
including the development of restriction from greater
adiposity around the chest wall and abdomen. This can
result in reduced total lung capacity and most notably,
low expiratory reserve volume, from upward diaphrag-
matic displacement due to increased abdominal fat; con-
sequently, airway closure occurs at or above functional
residual capacity in the dependent lung zones, which
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[15]. Although obesity is not associated with more air-
way obstruction, some studies have found it to be a risk
factor for greater bronchial hyperresponsiveness [3]. In
the Veterans Health Normative Aging Study, having a
BMI > 29 was associated with a ten-fold increase in odds
for developing methacholine responsiveness [16]. Whether
or not asthma and obesity synergistically increase bron-
chial hyperresponsiveness (BHR) has not been consistently
shown [3]; however, there is evidence that both conditions
jointly act to impair the degree of bronchodilation after
a deep inhalation (DI), which is a mechanical airway
dysfunction that in asthmatics has been associated with
increased indices of airway inflammation (See Table 1)
[17–19].
Yet the fact that not every obese asthmatic experiences
an increase in asthma severity suggests that other non-
mechanical factors are also involved. Broadly speaking, it
has been previously proposed that obesity, as a chronic
systemic inflammatory disorder, could affect asthma by
enhancing airway inflammation. However, clinical and
epidemiological studies have shown that this assertion is
far more complicated and unlikely to be explained by an
interaction between classical markers of systemic and
airway inflammation [20]. In cross-sectional studies, it
has been shown that with increasing BMI there is either
no change or a reduction in the percentage of airway eo-
sinophils [21, 22]. Indeed, analysis of nearly 1000 patients
undergoing repeated sputum samples from the Asthma
Clinical Research Networks, showed that compared to the
overweight and lean categories, the obese category hadTable 1 Implications of obesity and the relationship with asthma. O
adipose tissue, including mechanical or physiologic effects on lung
response and metabolic effects. The combination of these alteration
asthmatic
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bronchial dithe largest proportion of non-eosinophilic asthmatics [23].
However, this phenomenon may not necessarily reflect an
absolute reduction of airway eosinophils in obesity, but ra-
ther, reduced migration into the airway lumen. This obser-
vation was shown in a recent study of severe asthmatics
by Desai et al, in which obesity was associated with in-
creased sub-mucosal eosinophils (yet not in the airway
lumen) and with greater IL-5 sputum levels [24]. This
phenomenon in obese asthmatics may be due to altered
eosinophil survival or clearance or possibly a functional
change in eosinophil response to cytokines or chemokines.
In contrast, obesity has been associated with increased air-
way neutrophilia [25]. Given these results, it would appear
that the obesity-mediated changes in airway inflammation
are more consistent with a non-predominant Th-2 pheno-
type, and potentially a more Th-1 polarized immune re-
sponse [26]. Immune innate cells that produce IL-17 have
been implicated in murine obese models and detected in
human bronchoalveolar lavage fluid (BAL) and may con-
stitute yet another non-Th2 pathway [27]. With increasing
adiposity, there is a corresponding increase in leptin and a
reduction in adiponectin. Both of these changes have been
implicated in the obese – asthma pathogenesis [28].
Leptin is readily detected in the airways, is higher
among asthmatics, and increases in relation to plasma
leptin levels and BMI [29, 30]. Human airway epithelial
cells express leptin receptors, which are reduced with
increased asthma severity, and are associated with air-
way remodeling changes [31]. Peripherally, the magni-
tude of leptin receptor expression in visceral fat has
been related to BHR, which has led to the concept thatbese asthmatics have multiple consequences related to excess
function and the airways as well as changes in the immune
s contributes to the phenotypic characteristics of the obese
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tissues [32]. Ex vivo, leptin has been shown to increase the
oxidative and inflammatory response of alveolar macro-
phages derived from overweight and obese asthmatics [30];
however, whether or not increased airway leptin is associ-
ated with greater BHR, airway oxidative stress, or a dimin-
ished response to steroids is not known. Adiponectin, on
the other hand, is thought to have protective effects. It can
also be found in the airways, yet it does not closely relate
to BMI or plasma levels [29]. In females, higher plasma
adiponectin levels are associated with decreased asthma
risk [33], yet whether it has any anti-inflammatory or im-
mune modulator effects in the human airway is not clear;
or whether its plasma or airway levels are related to poor
asthma control, is not known (See Table 1 and Fig. 1).
Oxidative stress and metabolic dysregulation
It is widely known that both asthma and obesity are
chronic diseases characterized by greater oxidative stress;
however, it is not known whether this is synergistically in-
creased by both conditions. Because the majority of re-
search has been related to inflammation and immunity, a
potential role for metabolic derangements, as a source of
oxidative stress, has been greatly overlooked. With this in
mind, one potential area that may have particular relevance
to the obese-asthma association is related to changes in ni-
tric oxide (NO) metabolism. There is an inverse linearFig. 1 Mechanisms of Obese Asthma. A variety of mechanisms have been
obese asthmatics, including changes in adipokines; T-helper type 1 (Th-1) ske
L-arginine ratio resulting in increased oxidative stress and decreased physiolo
functional residual capacity and expiratory reserved volume due to excess ab
steroid resistance and dampened response to mitogen-activated protein (MAassociation between exhaled NO (eNO) with increasing
BMI in late onset (after childhood) asthmatics compared
to early onset [34]. Interestingly, this association has also
been described in children [35]. This inverse association
may be secondary to an imbalance between L-arginine, the
precursor of NO and substrate for inducible nitric oxide
synthase (iNOS), and asymmetric di-methyl arginine
(ADMA), which is an endogenous inhibitor of all NOS
enzymes that produce NO [34]. Lower L-arginine might
result from increased arginase activity, which is associated
with asthma severity, and increased ADMA has been re-
lated to obesity and metabolic syndrome [36, 37]. As a
result of having lower L-arginine/ADMA ratios, obese
asthmatics produce less NO and more anion superoxide
from iNOS uncoupling in which electrons are shifted to
molecular oxygen rather than toward production of NO
[38]. Having lower airway NO bioavailability at baseline
may impair the degree of physiological bronchial dilation,
leading to increased respiratory symptoms [39]. Indeed,
increased airway and systemic ADMA is inversely associ-
ated with eNO [40] and in the SARP study population,
with more frequent respiratory symptoms, poorer quality
of asthma and lower lung function [34].
Steroid resistance
Post hoc analyses of clinical trials have shown that the
response to inhaled steroids is different across BMIproposed as drivers of the physiologic and clinical observations in
wed airway inflammation; lower asymmetric dimethylarginine (ADMA) to
gic nitric oxide (NO), a mediator in smooth muscle dilatation; reduced
dominal adiposity; interleukin-17 (IL-17) associated airway inflammation;
P) kinase phosphatase-1 (MKP-1)
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categories, obese and morbidly obese subjects have a re-
duced percentage change in FEV1 after starting inhaled
corticosteroids (ICS); moreover, there is an inverse associ-
ation between the percent of asthma control days (ACD)
and BMI, among subjects randomized to ICS, leukotriene
blockers, or placebo [43]. Although it appeared that the ef-
fect of BMI on ACD was less for subjects randomized to
the leukotriene arm, subsequent studies have shown
that response to this medication is not modified by BMI
categories. The reduced steroid response in obese asth-
matics could be secondary to increased resistance; as
shown by Sutherland et al, who showed that being obese
was associated with an in vitro blunted response to
dexamethasone-induced mitogen-activated protein (MAP)
kinase phosphatase-1 (MKP-1) and baseline tumor necro-
sis factor (TNF)-alpha in peripheral blood mononuclear
cells (PBMCs) and bronchoalveolar lavage cells.
Obesity – mediated steroid resistance could also be sec-
ondary to low vitamin D levels, which are known to be in-
versely related to BMI and associated with increased
asthma morbidity [44]. Early studies in asthmatic children
and adults suggested that vitamin D deficiency is associ-
ated with lung function impairment, worse AHR, more se-
vere asthma, and decreased response to corticosteroid
therapy [44–46]. However, in the recent National Insti-
tutes of Health (NIH) AsthmaNet Clinical Trial of Vita-
min D Supplementation in Asthma (VIDA), vitamin D
was not more effective on obese asthmatics. Specifically,
the VIDA study, a randomized, double-blind, parallel,
placebo-controlled trial sought to determine if vitamin
supplementation in asthmatics using inhaled corticoste-
roids improved asthma outcomes with a primary out-
come of time to first asthma treatment failure (based on
decline in lung function and increased use of beta-
agonists or systemic corticosteroids, and increased health-
care utilization). In this study, when comparing those
asthmatics with BMI < 25 versus BMI ≥ 25, vitamin D sup-
plementation did not show a reduction in asthma treat-
ment failures in the obese group [47].
Ultimately, increased steroid resistance may explain why,
even when adequately treated, asthmatics – regardless of
severity - with a BMI > 25 are less likely to transition from
an uncontrolled state to a controlled state over time [48].
The longitudinal SARP study, currently underway, which is
a multicenter observational study of moderate and severe
asthmatics, will provide important information as to how
BMI influences the response to systemic steroids in chil-
dren and adults with asthma [49].
Co-morbidities (obstructive sleep apnea, gastroesophageal
reflux disease, and metabolic syndrome)
Becoming obese increases the risk for other chronic ill-
nesses, which are also linked to increased risk of asthma orworsened respiratory symptoms. Data from the American
Lung Association Clinical Trials Network showed in a
post hoc analysis involving 402 patients, that obstructive
sleep apnea (OSA), but not gastroesophageal reflux dis-
ease (GERD), was associated with poor asthma control.
Other studies have also shown that OSA can contribute to
asthma control and severity [50, 51]. Together, these data
make a strong case for OSA as a potential mechanistic
pathway for obesity and greater asthma morbidity in
some patients. Depression is another co-morbidity that
is more common in obese subjects, is independently as-
sociated with poor control, and in one study, it has been
shown to mediate symptoms between increased BMI
and asthma [52, 53].
An important confounder to the obese – asthma asso-
ciation is metabolic syndrome (MetSyn), which occurs
in ~20 % of the general population and 60 % of obese
subjects. It is defined as having at least 3 out of 5 of the
following: a) glucose intolerance, b) hypertension, c)
abdominal obesity, d) dyslipidemia – low high density
lipoprotein (HDL), and hypertriglyceridemia [54]. The
MetSyn has been related to asthma independently of
BMI; in the Nord-Trøndelag Health Study (HUNT) study,
a large European cohort study, MetSyn diagnosis was as-
sociated with incident asthma after adjusting for BMI
[55]. However, whether the obese – asthma relation is ex-
plained by MetSyn remains controversial. In a large study
of 4,619 eligible participants in the Coronary Artery Risk
Development in Young Adults (CARDIA) cohort followed
over 25 years, MetSyn predicted asthma incidence in
women, but this association was found to be mostly con-
founded by BMI [56].
Treating the obese asthmatic
While there are no pharmacologic strategies to specific-
ally treat obese asthmatics, weight loss interventions,
both surgical and nutritional, have been tested and shown
to have varying degrees of effectiveness in improving the
respiratory health of these patients. The BMI reduction in
one year following bariatric surgery has been shown to
significantly improve average ACQ and ACT scores [57,
58]. However, in one study, BHR improved only among
patients with low or normal IgE levels, suggesting that dif-
ferent phenotypes may differentially benefit from weight
loss [58]. In a randomized clinical trial for children with
asthma, a short term dietary intervention based on caloric
restriction significantly improved asthma control when
compared to the control group; ACQ improved signifi-
cantly in the diet intervention group when compared to
the wait listed control group (-0.4 [-0.7, 0.0] vs. 0.1 [0.0,
0.6], P = 0.004) [59]. According to a Cochrane meta-
analysis, weight loss interventions can improve outcomes
in overweight or obese asthmatics, however, the majority
of studies suffered from severe design flaws [60]. In a
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asthma were randomized to usual care versus usual care
plus a 12-month intervention targeted at weight loss
and increased physical activity for asthma control. The
primary outcome was change in ACQ from baseline to
12 months. This study showed that weight loss of at
least 10 % or greater was associated with improvement
in ACQ and clinical improvement in asthma [61]. An
important question, which remains to be answered, is
whether weight loss improves response to inhaled or
systemic corticosteroids.Conclusions
 Obesity may be a risk factor for increased asthma
severity and poor control in a subgroup, but not all
patients
 It is unlikely that there is one unique obese –
asthma phenotype
 The relationship between obesity and asthma is
bi-directional
 Patient susceptibility to obesity-mediated effects on
asthma may depend on the interaction with other
demographic and clinical factors, such as gender,
race, age of asthma onset, and atopy.
 There are multiple potential mechanisms yet there is
not a unified consensus as to which are more
clinically relevant or how they may work in parallel.
 Weight loss is the only available specific
intervention to treat the effects of obesity on
asthma. The effectiveness of this intervention may
depend on other phenotypical factors and the
degree of weight loss.
 Studies involving weight loss should be undertaken
to test the clinical and biological relevance of
proposed mechanistic pathways between obesity
and asthma.
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